Skip to main content
. 2012 Dec 18;22(9):1329–1341. doi: 10.1089/scd.2012.0255

FIG. 4.

FIG. 4.

MSC immunoregulatory effects on B cells. (A) Purified B-cells from healthy individuals were cultured in the absence or presence of allogeneic normal or patient-derived MSCs. Cumulative data depicting the mean (±SEM) percentage of viable (7AAD−) CD19+ cells cultured alone or co-cultured with MSCs is shown (B) CFSE-labeled B-cells from healthy individuals were cultured alone or in the presence of MSCs, as mentioned earlier, in the presence of CpG 2006 oligonucleotide and IL-2. Cumulative data showing the mean percentage (±SEM) of proliferating CFSE+CD19+ cells are depicted (C) Cumulative data indicating the mean (±SEM) IgG levels in supernatants of B-cells from healthy individuals cultured alone or in the presence of MSCs as previously mentioned, in the presence of CpG 2006 oligonucleotide and IL-2. (D) PBMCs from CLL patients were cultured in the absence or presence of allogeneic patient or normal-derived MSCs. Cumulative data depicting the mean (±SEM) percentage of viable (7AAD−) CD19+ cells are shown. PBMCs, peripheral blood mononuclear cells; CFSE, carboxy-fluorescein succinic-midyl ester; SEM, standard error of the mean; *P<0.05.